{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:08:21Z","timestamp":1790726901411,"version":"4.1.0"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"EU Framework Programme for Research and Innovation Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["955879"],"award-info":[{"award-number":["955879"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["slas-discovery.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["SLAS Discovery"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.slasd.2026.100338","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T23:57:40Z","timestamp":1789516660000},"page":"100338","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["From phenotypic screening to target and compound prioritization for autosomal dominant polycystic kidney disease"],"prefix":"10.1016","volume":"44","author":[{"given":"David Alencar","family":"Araripe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Iljin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9750-5186","authenticated-orcid":false,"given":"Hester","family":"Bange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo S.","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0136-8811","authenticated-orcid":false,"given":"Rongfang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daan","family":"van der Es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura H.","family":"Heitman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorien J.M.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0717-1817","authenticated-orcid":false,"given":"Gerard J.P.","family":"van Westen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.slasd.2026.100338_bib0001","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.34067\/KID.0004522021","article-title":"Autosomal dominant polycystic kidney disease prevalence among a racially diverse United States population, 2002 through 2018","volume":"2","author":"Aung","year":"2021","journal-title":"Kidney360"},{"issue":"1","key":"10.1016\/j.slasd.2026.100338_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000112495","article-title":"Autosomal dominant polycystic kidney disease: recent advances in pathogenesis and treatment","volume":"108","author":"Chang","year":"2008","journal-title":"Nephron Physiol"},{"issue":"4","key":"10.1016\/j.slasd.2026.100338_bib0003","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1083\/jcb.201006173","article-title":"The cell biology of polycystic kidney disease","volume":"191","author":"Chapin","year":"2010","journal-title":"J Cell Biol"},{"issue":"4","key":"10.1016\/j.slasd.2026.100338_bib0004","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/17557380241311211","article-title":"Polycystic Kidney disease","volume":"18","author":"Ansari","year":"2025","journal-title":"InnovAiT"},{"issue":"1","key":"10.1016\/j.slasd.2026.100338_bib0005","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1681\/ASN.2017050483","article-title":"Genetic complexity of autosomal dominant polycystic kidney and liver diseases","volume":"29","author":"Cornec-Le Gall","year":"2018","journal-title":"J Am Soc Nephrol"},{"issue":"21","key":"10.1016\/j.slasd.2026.100338_bib0006","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1042\/CS20210370","article-title":"Recent advances in understanding ion transport mechanisms in polycystic kidney disease","volume":"135","author":"Sudarikova","year":"2021","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.slasd.2026.100338_bib0007","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.981963","article-title":"Emerging therapies for autosomal dominant polycystic kidney disease with a focus on cAMP signaling","volume":"9","author":"Zhou","year":"2022","journal-title":"Front Mol Biosci"},{"issue":"2","key":"10.1016\/j.slasd.2026.100338_bib0008","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0272-6386(12)80507-5","article-title":"Polycystic Kidney disease: neoplasia in disguise","volume":"15","author":"Grantham","year":"1990","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"10.1016\/j.slasd.2026.100338_bib0009","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/nrneph.2015.46","article-title":"The hallmarks of cancer: relevance to the pathogenesis of polycystic kidney disease","volume":"11","author":"Seeger-Nukpezah","year":"2015","journal-title":"Nat Rev Nephrol"},{"issue":"3","key":"10.1016\/j.slasd.2026.100338_bib0010","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1053\/j.akdh.2023.01.003","article-title":"Autosomal dominant polycystic kidney disease therapies on the horizon","volume":"30","author":"Zhou","year":"2023","journal-title":"Adv Kidney Dis Health"},{"issue":"1","key":"10.1016\/j.slasd.2026.100338_bib0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1527-3466.2007.00001.x","article-title":"Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials","volume":"25","author":"Miyazaki","year":"2007","journal-title":"Cardiovasc Drug Rev"},{"issue":"7","key":"10.1016\/j.slasd.2026.100338_bib0012","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrd3480","article-title":"How were new medicines discovered?","volume":"10","author":"Swinney","year":"2011","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"10.1016\/j.slasd.2026.100338_bib0013","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1177\/2472555217716056","article-title":"High-throughput phenotypic screening of kinase inhibitors to identify drug targets for polycystic kidney disease","volume":"22","author":"Booij","year":"2017","journal-title":"SLAS Discov"},{"issue":"8","key":"10.1016\/j.slasd.2026.100338_bib0014","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1093\/jmcb\/mjz029","article-title":"In vitro 3D phenotypic drug screen identifies celastrol as an effective in vivo inhibitor of polycystic kidney disease","volume":"12","author":"Booij","year":"2020","journal-title":"J Mol Cell Biol"},{"issue":"5","key":"10.1016\/j.slasd.2026.100338_bib0015","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.kint.2023.01.026","article-title":"A novel direct adenosine monophosphate kinase activator ameliorates disease progression in preclinical models of autosomal dominant polycystic kidney disease","volume":"103","author":"Dagorn","year":"2023","journal-title":"Kidney Int"},{"key":"10.1016\/j.slasd.2026.100338_bib0016","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1397864","article-title":"Computational drug discovery approaches identify Mebendazole as a candidate treatment for autosomal dominant polycystic kidney disease","volume":"15","author":"Brownjohn","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.slasd.2026.100338_bib0017","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/978-3-319-51436-9_12","article-title":"Inflammation and fibrosis in polycystic kidney disease","volume":"60","author":"Song","year":"2017","journal-title":"Results Probl Cell Differ"},{"issue":"D1","key":"10.1016\/j.slasd.2026.100338_bib0018","doi-asserted-by":"crossref","first-page":"D1180","DOI":"10.1093\/nar\/gkad1004","article-title":"The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods","volume":"52","author":"Zdrazil","year":"2024","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"10.1016\/j.slasd.2026.100338_bib0019","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13321-022-00672-x","article-title":"Papyrus: a large-scale curated dataset aimed at bioactivity predictions","volume":"15","author":"B\u00e9quignon","year":"2023","journal-title":"J Cheminform"},{"issue":"1","key":"10.1016\/j.slasd.2026.100338_bib0020","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1145\/1656274.1656280","article-title":"KNIME - the Konstanz information miner: version 2.0 and beyond","volume":"11","author":"Berthold","year":"2009","journal-title":"SIGKDD Explor Newsl"},{"key":"10.1016\/j.slasd.2026.100338_bib0021","article-title":"Statannotations, version 0.7.1","author":"Charlier","year":"2024","journal-title":"Zenodo"},{"issue":"1","key":"10.1016\/j.slasd.2026.100338_bib0022","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13321-024-00908-y","article-title":"QSPRpred: a flexible open-source quantitative structure-property relationship modelling tool","volume":"16","author":"van den Maagdenberg","year":"2024","journal-title":"J Cheminform"},{"issue":"4","key":"10.1016\/j.slasd.2026.100338_bib0023","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1021\/acs.jcim.2c01253","article-title":"ZINC-22\u2013A free multi-billion-scale database of tangible compounds for Ligand discovery","volume":"63","author":"Tingle","year":"2023","journal-title":"J Chem Inf Model"},{"issue":"7877","key":"10.1016\/j.slasd.2026.100338_bib0024","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/s41586-021-03897-2","article-title":"Positive allosteric mechanisms of adenosine A1 receptor-mediated analgesia","volume":"597","author":"Draper-Joyce","year":"2021","journal-title":"Nature"},{"issue":"1\u20133","key":"10.1016\/j.slasd.2026.100338_bib0025","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejphar.2010.03.018","article-title":"The l-, N-, and T-type triple calcium channel blocker benidipine acts as an antagonist of mineralocorticoid receptor, a member of nuclear receptor Family","volume":"635","author":"Kosaka","year":"2010","journal-title":"Eur J Pharmacol"},{"issue":"12","key":"10.1016\/j.slasd.2026.100338_bib0026","doi-asserted-by":"crossref","first-page":"8127","DOI":"10.1021\/acs.jmedchem.2c00402","article-title":"Discovery of Apararenone (MT-3995) as a highly selective, potent, and novel nonsteroidal mineralocorticoid receptor antagonist","volume":"65","author":"Iijima","year":"2022","journal-title":"J Med Chem"},{"issue":"11","key":"10.1016\/j.slasd.2026.100338_bib0027","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1021\/acschembio.2c00589","article-title":"A chemical biological approach to study G protein-coupled receptors: labeling the adenosine A1 receptor using an electrophilic covalent probe","volume":"17","author":"Beerkens","year":"2022","journal-title":"ACS Chem Biol"},{"issue":"9","key":"10.1016\/j.slasd.2026.100338_bib0028","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1080\/17460441.2024.2376643","article-title":"Polypharmacology prediction: the long road toward comprehensively anticipating small-molecule selectivity to de-risk drug discovery","volume":"19","author":"Manen-Freixa","year":"2024","journal-title":"Expert Opin Drug Discov"},{"issue":"7","key":"10.1016\/j.slasd.2026.100338_bib0029","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/j.bmcl.2016.02.050","article-title":"Identification of novel GLUT inhibitors","volume":"26","author":"Siebeneicher","year":"2016","journal-title":"Bioorg Med Chem Lett"},{"issue":"6","key":"10.1016\/j.slasd.2026.100338_bib0030","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1111\/bph.12342","article-title":"Rolofylline, an Adenosine A1 receptor antagonist, inhibits osteoclast differentiation as an inverse agonist: rolofylline acts as an inverse agonist","volume":"170","author":"He","year":"2013","journal-title":"Br J Pharmacol"},{"issue":"1\u20133","key":"10.1016\/j.slasd.2026.100338_bib0031","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejphar.2012.04.008","article-title":"Evidence for constitutively-active adenosine receptors at mammalian motor nerve endings","volume":"685","author":"Searl","year":"2012","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"10.1016\/j.slasd.2026.100338_bib0032","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/nm.3092","article-title":"Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy","volume":"19","author":"Rowe","year":"2013","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.slasd.2026.100338_bib0033","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00424-004-1264-7","article-title":"The SLC2 Family of facilitated hexose and polyol transporters","volume":"448","author":"Uldry","year":"2004","journal-title":"Pflug Arch"},{"issue":"4","key":"10.1016\/j.slasd.2026.100338_bib0034","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.3233\/JAD-160841","article-title":"Glucose transporters in brain: in health and in Alzheimer\u2019s disease","volume":"55","author":"Szablewski","year":"2016","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"10.1016\/j.slasd.2026.100338_bib0035","doi-asserted-by":"crossref","first-page":"76","DOI":"10.5527\/wjn.v5.i1.76","article-title":"Role of calcium in polycystic kidney disease: from signaling to pathology","volume":"5","author":"Mangolini","year":"2016","journal-title":"World J Nephrol"},{"issue":"1","key":"10.1016\/j.slasd.2026.100338_bib0036","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11302-023-09941-2","article-title":"Fetal bovine serum contains biologically available ATP","volume":"20","author":"Vultaggio-Poma","year":"2024","journal-title":"Purinergic Signal"},{"issue":"26","key":"10.1016\/j.slasd.2026.100338_bib0037","doi-asserted-by":"crossref","first-page":"6529","DOI":"10.1021\/jm049448r","article-title":"2,4,6-Trisubstituted pyrimidines as a new class of selective Adenosine A1 receptor antagonists","volume":"47","author":"Chang","year":"2004","journal-title":"J Med Chem"},{"issue":"3","key":"10.1016\/j.slasd.2026.100338_bib0038","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s11302-015-9460-9","article-title":"Selectivity is species-dependent: characterization of standard agonists and antagonists at Human, rat, and mouse adenosine receptors","volume":"11","author":"Alnouri","year":"2015","journal-title":"Purinergic Signal"},{"issue":"3","key":"10.1016\/j.slasd.2026.100338_bib0039","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nrd1983","article-title":"Adenosine receptors as therapeutic targets","volume":"5","author":"Jacobson","year":"2006","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"10.1016\/j.slasd.2026.100338_bib0040","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0006-2952(00)00536-0","article-title":"Differential effects of the allosteric enhancer (2-Amino-4,5-Dimethyl-Trienyl)[3-(Trifluoromethyl) Phenyl]methanone (PD81,723) on agonist and antagonist binding and function at the Human wild-type and a mutant (T277A) Adenosine A1 receptor","volume":"61","author":"Kourounakis","year":"2001","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"10.1016\/j.slasd.2026.100338_bib0041","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s10020-023-00664-z","article-title":"Prioritized polycystic kidney disease drug targets and repurposing candidates from pre-cystic and cystic mouse Pkd2 model gene expression reversion","volume":"29","author":"Wilk","year":"2023","journal-title":"Mol Med"},{"issue":"6","key":"10.1016\/j.slasd.2026.100338_bib0042","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1038\/ki.2014.427","article-title":"Glycogen synthase kinase-3\u03b2 promotes cyst expansion in polycystic kidney disease","volume":"87","author":"Tao","year":"2015","journal-title":"Kidney Int"},{"issue":"suppl_1","key":"10.1016\/j.slasd.2026.100338_bib0043","article-title":"Fp110a Phase 2 trial of the safety and efficacy of bardoxolone methyl in patients with rare chronic kidney diseases","volume":"33","author":"Pergola","year":"2018","journal-title":"Nephrol Dial Transplant"},{"issue":"554","key":"10.1016\/j.slasd.2026.100338_bib0044","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba3613","article-title":"Activation of NRF2 ameliorates oxidative stress and cystogenesis in autosomal dominant polycystic kidney disease","volume":"12","author":"Lu","year":"2020","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/j.slasd.2026.100338_bib0045","doi-asserted-by":"crossref","first-page":"F997","DOI":"10.1152\/ajprenal.00186.2017","article-title":"An inhibitor of histone deacetylase 6 activity, ACY-1215, reduces cAMP and cyst growth in polycystic kidney disease","volume":"313","author":"Yanda","year":"2017","journal-title":"Am J Physiol Renal Physiol"},{"issue":"1","key":"10.1016\/j.slasd.2026.100338_bib0046","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.kint.2016.01.026","article-title":"Inhibition of histone deacetylase 6 activity reduces cyst growth in polycystic kidney disease","volume":"90","author":"Cebotaru","year":"2016","journal-title":"Kidney Int"},{"issue":"43","key":"10.1016\/j.slasd.2026.100338_bib0047","doi-asserted-by":"crossref","first-page":"17897","DOI":"10.1074\/jbc.M117.803775","article-title":"Histone deacetylase 6 inhibition reduces cysts by decreasing cAMP and Ca2+ in knock-out mouse models of polycystic Kidney disease","volume":"292","author":"Yanda","year":"2017","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.slasd.2026.100338_bib0048","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1053\/j.akdh.2023.03.001","article-title":"Mechanisms of cyst development in polycystic kidney disease","volume":"30","author":"Qiu","year":"2023","journal-title":"Adv Kidney Dis Health"},{"issue":"5","key":"10.1016\/j.slasd.2026.100338_bib0049","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.ajpath.2021.01.011","article-title":"Up-regulation of DNA damage response signaling in autosomal dominant polycystic kidney disease","volume":"191","author":"Zhang","year":"2021","journal-title":"Am J Pathol"},{"issue":"5","key":"10.1016\/j.slasd.2026.100338_bib0050","doi-asserted-by":"crossref","first-page":"5257","DOI":"10.1021\/acs.jmedchem.4c02128","article-title":"Design of selective BRD4 inhibitors for the treatment of autosomal dominant polycystic kidney disease","volume":"68","author":"Yang","year":"2025","journal-title":"J Med Chem"},{"issue":"6","key":"10.1016\/j.slasd.2026.100338_bib0051","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1681\/ASN.2021081125","article-title":"Protein kinase A downregulation delays the development and progression of polycystic kidney disease","volume":"33","author":"Wang","year":"2022","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.slasd.2026.100338_bib0052","doi-asserted-by":"crossref","first-page":"F1649","DOI":"10.1152\/ajprenal.00395.2019","article-title":"Knockout of P2rx7 purinergic receptor attenuates cyst growth in a rat model of ARPKD","volume":"317","author":"Arkhipov","year":"2019","journal-title":"Am J Physiol Renal Physiol"},{"issue":"9","key":"10.1016\/j.slasd.2026.100338_bib0053","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1681\/ASN.2010070728","article-title":"Inhibition of the P2X7 receptor reduces cystogenesis in PKD","volume":"22","author":"Chang","year":"2011","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.slasd.2026.100338_bib0054","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1182\/blood-2004-08-3247","article-title":"A novel NF-kappaB inhibitor, IMD-0354, suppresses neoplastic proliferation of Human mast cells with constitutively activated c-kit receptors","volume":"105","author":"Tanaka","year":"2005","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.slasd.2026.100338_bib0055","doi-asserted-by":"crossref","first-page":"6164","DOI":"10.1021\/acs.jmedchem.0c00435","article-title":"Discovery and structure relationships of salicylanilide derivatives as potent, non-acidic P2X1 receptor antagonists","volume":"63","author":"Tian","year":"2020","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/j.slasd.2026.100338_bib0056","doi-asserted-by":"crossref","first-page":"4203","DOI":"10.1038\/s41598-020-61082-3","article-title":"A high-throughput screening platform for polycystic kidney disease (PKD) drug repurposing utilizing murine and Human ADPKD cells","volume":"10","author":"Asawa","year":"2020","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.slasd.2026.100338_bib0057","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s40620-017-0395-9","article-title":"Defective glycolysis and the use of 2-deoxy-d-glucose in polycystic kidney disease: from animal models to humans","volume":"30","author":"Magistroni","year":"2017","journal-title":"J Nephrol"},{"key":"10.1016\/j.slasd.2026.100338_bib0058","article-title":"Metabolic reprogramming and reconstruction: integration of experimental and computational studies to set the path forward in ADPKD","volume":"8","author":"Pagliarini","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.slasd.2026.100338_bib0059","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2024.111351","article-title":"Early Treatment with 2-deoxy-d-glucose reduces proliferative proteins in the kidney and slows cyst growth in a hypomorphic Pkd1 mouse model of autosomal dominant polycystic Kidney disease (PKD)","volume":"123","author":"Atwood","year":"2024","journal-title":"Cell Signal"},{"issue":"10","key":"10.1016\/j.slasd.2026.100338_bib0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2018.e00829","article-title":"Xanthine scaffold: scope and potential in drug development","volume":"4","author":"Singh","year":"2018","journal-title":"Heliyon"},{"issue":"6","key":"10.1016\/j.slasd.2026.100338_bib0061","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.bbadis.2009.03.001","article-title":"Deficiency of polycystic Kidney disease-1 gene (PKD1) expression increases A(3) adenosine receptors in Human renal cells: implications for cAMP-dependent signalling and proliferation of PKD1-mutated cystic cells","volume":"1792","author":"Aguiari","year":"2009","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"10.1016\/j.slasd.2026.100338_bib0062","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1038\/s41467-024-47207-6","article-title":"Cryo-EM structures of adenosine receptor A3AR bound to selective agonists","volume":"15","author":"Cai","year":"2024","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.slasd.2026.100338_bib0063","doi-asserted-by":"crossref","first-page":"7717","DOI":"10.1021\/acs.jmedchem.2c00011","article-title":"Long residence time at the Vasopressin V2 receptor translates into superior inhibitory effects in ex vivo and in vivo models of autosomal dominant polycystic kidney disease","volume":"65","author":"Zhang","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.slasd.2026.100338_bib0064","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ejphar.2015.06.015","article-title":"Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist","volume":"761","author":"Arai","year":"2015","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"10.1016\/j.slasd.2026.100338_bib0065","doi-asserted-by":"crossref","first-page":"549","DOI":"10.3390\/biomedicines9050549","article-title":"Characterization of direct perturbations on voltage-gated sodium current by Esaxerenone, a nonsteroidal mineralocorticoid receptor blocker","volume":"9","author":"Chang","year":"2021","journal-title":"Biomedicines"},{"issue":"10","key":"10.1016\/j.slasd.2026.100338_bib0066","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1002\/1873-3468.13746","article-title":"Crystal structure of the mineralocorticoid receptor ligand-binding domain in complex with a potent and selective nonsteroidal blocker, esaxerenone (CS-3150)","volume":"594","author":"Takahashi","year":"2020","journal-title":"FEBS Lett"},{"issue":"1","key":"10.1016\/j.slasd.2026.100338_bib0067","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1210\/mend.13.1.0226","article-title":"Modulation of Human mineralocorticoid receptor function by protein kinase A","volume":"13","author":"Massaad","year":"1999","journal-title":"Mol Endocrinol"},{"issue":"6","key":"10.1016\/j.slasd.2026.100338_bib0068","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1253\/circrep.CR-21-0024","article-title":"Renoprotective effect of the mineralocorticoid receptor antagonist esaxerenone","volume":"3","author":"Oshima","year":"2021","journal-title":"Circ Rep"},{"issue":"8","key":"10.1016\/j.slasd.2026.100338_bib0069","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/nep.12658","article-title":"KHA-CARI guideline recommendations for the diagnosis and management of autosomal dominant polycystic kidney disease","volume":"21","author":"Rangan","year":"2016","journal-title":"Nephrology (Carlton)"},{"issue":"9","key":"10.1016\/j.slasd.2026.100338_bib0070","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1007\/s13300-021-01118-7","article-title":"Effect of mineralocorticoid receptor antagonism and ACE inhibition on angiotensin profiles in diabetic kidney disease: an exploratory study","volume":"12","author":"Kovarik","year":"2021","journal-title":"Diabetes Ther"},{"issue":"12","key":"10.1016\/j.slasd.2026.100338_bib0071","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.2215\/CJN.06870520","article-title":"Esaxerenone (CS-3150) in patients with type 2 diabetes and microalbuminuria (ESAX-DN): phase 3 randomized controlled clinical trial","volume":"15","author":"Ito","year":"2020","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["SLAS Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2472555226000444?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2472555226000444?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:47:02Z","timestamp":1790725622000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2472555226000444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":71,"alternative-id":["S2472555226000444"],"URL":"https:\/\/doi.org\/10.1016\/j.slasd.2026.100338","relation":{},"ISSN":["2472-5552"],"issn-type":[{"value":"2472-5552","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From phenotypic screening to target and compound prioritization for autosomal dominant polycystic kidney disease","name":"articletitle","label":"Article Title"},{"value":"SLAS Discovery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.slasd.2026.100338","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of Society for Laboratory Automation and Screening.","name":"copyright","label":"Copyright"}],"article-number":"100338"}}